"Dec. 2, 2010 -- Babies born to women who take the antiseizure drug carbamazepine have a more than twofold increased risk for the birth defect spina bifida, a study shows.
But researchers say the drug still has less risk of birth defects"...
Tegretol is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of Tegretol as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types:
- Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types.
- Generalized tonic-clonic seizures (grand mal).
- Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by Tegretol (see PRECAUTIONS, General).
Tegretol is indicated in the treatment of the pain associated with true trigeminal neuralgia.
Beneficial results have also been reported in glossopharyngeal neuralgia.
This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains.
DOSAGE AND ADMINISTRATION
(See Table Below)
Tegretol suspension in combination with liquid chlorpromazine or thioridazine results in precipitate formation, and, in the case of chlorpromazine, there has been a report of a patient passing an orange rubbery precipitate in the stool following coadministration of the two drugs (see PRECAUTIONS: DRUG INTERACTIONS). Because the extent to which this occurs with other liquid medications is not known, Tegretol suspension should not be administered simultaneously with other liquid medications or diluents.
Monitoring of blood levels has increased the efficacy and safety of anticonvulsants (see PRECAUTIONS, Laboratory Tests). Dosage should be adjusted to the needs of the individual patient. A low initial daily dosage with a gradual increase is advised. As soon as adequate control is achieved, the dosage may be reduced very gradually to the minimum effective level. Medication should be taken with meals.
Since a given dose of Tegretol suspension will produce higher peak levels than the same dose given as the tablet, it is recommended to start with low doses (children 6-12 years: ½ teaspoon q.i.d.) and to increase slowly to avoid unwanted side effects.
Conversion of patients from oral Tegretol tablets to Tegretol suspension: Patients should be converted by administering the same number of mg per day in smaller, more frequent doses (i.e., b.i.d. tablets to t.i.d. suspension).
Tegretol-XR is an extended-release formulation for twice-a-day administration. When converting patients from Tegretol conventional tablets to Tegretol-XR, the same total daily mg dose of Tegretol-XR should be administered. Tegretol-XR tablets must be swallowed whole and never crushed or chewed. Tegretol-XR tablets should be inspected for chips or cracks. Damaged tablets, or tablets without a release portal, should not be consumed. Tegretol-XR tablet coating is not absorbed and is excreted in the feces; these coatings may be noticeable in the stool.
(See INDICATIONS AND USAGE)
Adults and children over 12 years of age - Initial: Either 200 mg b.i.d. for tablets and XR tablets, or 1 teaspoon q.i.d. for suspension (400 mg/day). Increase at weekly intervals by adding up to 200 mg/day using a b.i.d. regimen of Tegretol-XR or a t.i.d. or q.i.d. regimen of the other formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily in children 12-15 years of age, and 1200 mg daily in patients above 15 years of age. Doses up to 1600 mg daily have been used in adults in rare instances. Maintenance: Adjust dosage to the minimum effective level, usually 800-1200 mg daily.
Children 6-12 years of age - Initial: Either 100 mg b.i.d. for tablets or XR tablets, or ½ teaspoon q.i.d. for suspension (200 mg/day). Increase at weekly intervals by adding up to 100 mg/day using a b.i.d. regimen of Tegretol-XR or a t.i.d. or q.i.d. regimen of the other formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily. Maintenance: Adjust dosage to the minimum effective level, usually 400-800 mg daily.
Children under 6 years of age - Initial: 10-20 mg/kg/day b.i.d. or t.i.d. as tablets, or q.i.d. as suspension. Increase weekly to achieve optimal clinical response administered t.i.d. or q.i.d. Maintenance: Ordinarily, optimal clinical response is achieved at daily doses below 35 mg/kg. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the therapeutic range. No recommendation regarding the safety of carbamazepine for use at doses above 35 mg/kg/24 hours can be made.
Combination Therapy: Tegretol may be used alone or with other anticonvulsants. When added to existing anticonvulsant therapy, the drug should be added gradually while the other anticonvulsants are maintained or gradually decreased, except phenytoin, which may have to be increased (see PRECAUTIONS: DRUG INTERACTIONS, and Pregnancy Category D).
(See INDICATIONS AND USAGE)
Initial: On the first day, either 100 mg b.i.d. for tablets or XR tablets, or ½ teaspoon q.i.d. for suspension, for a total daily dose of 200 mg. This daily dose may be increased by up to 200 mg/day using increments of 100 mg every 12 hours for tablets or XR tablets, or 50 mg (½ teaspoon) q.i.d. for suspension, only as needed to achieve freedom from pain. Do not exceed 1200 mg daily. Maintenance: Control of pain can be maintained in most patients with 400-800 mg daily. However, some patients may be maintained on as little as 200 mg daily, while others may require as much as 1200 mg daily. At least once every 3 months throughout the treatment period, attempts should be made to reduce the dose to the minimum effective level or even to discontinue the drug.
|Indication||Initial Dose||Subsequent Dose||Maximum Daily Dose|
|Epilepsy Under 6 yr||10-20 mg/kg/day b.i.d. or t.i.d.||10-20 mg/kg/day q.i.d.||Increase weekly to achieve optimal clinical response, t.i.d. or q.i.d.||Increase weekly to achieve optimal clinical response, t.i.d. or q.i.d.||35 mg/kg/24 hr (see DOSAGE AND ADMINISTRATION section above||35 mg/kg/24 hr (see DOSAGE AND ADMINISTRATION section above|
|6-12 yr||100 mg b.i.d. (200 mg/day)||100 mg b.i.d. (200 mg/day)||% tsp q.i.d. (200 mg/day)||Add up to 100 mg/day at weekly intervals, t.i.d. or q.i.d.||Add 100 mg/day at weekly intervals, b.i.d.||Add up to 1 tsp (100 mg)/day at weekly intervals, t.i.d. or q.i.d.||1000 mg/24 hr|
|Over 12 yr||200 mg b.i.d. (400 mg/day)||200 mg b.i.d. (400 mg/day)||1 tsp q.i.d. (400 mg/day)||Add up to 200 mg/day at weekly intervals, t.i.d. or q.i.d.||Add up to 200 mg/day at weekly intervals, b.i.d.||Add up to 2 tsp (200 mg)/day at weekly intervals, t.i.d. or q.i.d.||1000 mg/24 hr (12-15 yr)
1200 mg/24 hr ( > 15 yr)
1600 mg/24 hr (adults, in rare instances)
|Trigeminal Neuralgia||100 mg b.i.d. (200 mg/day)||100 mg b.i.d. (200 mg/day)||% tsp q.i.d. (200 mg/day)||Add up to 200 mg/day in increments of 100 mg every 12 hr||Add up to 200 mg/day in increments of 100 mg every 12 hr||Add up to 2 tsp (200 mg)/day in increments of 50 mg (% tsp) q.i.d.||1200 mg/24 hr|
|*Tablet = Chewable or conventional tablets
†XR = Tegretol®-XR extended-release tablets
Chewable Tablets 100 mg - round, red-speckled, pink, single-scored (imprinted Tegretol on one side and 52 twice on the scored side)
Bottles of 100 ............................. NDC 0078-0492-05
Unit Dose (blister pack)
Box of 100 (strips of 10) ............ NDC 0078-0492-35
Do not store above 30°C (86°F). Protect from light and moisture.
Dispense in tight, light-resistant container (USP).
Meets USP Dissolution Test 1.
Tablets 200 mg - capsule-shaped, pink, single-scored (imprinted Tegretol on one side and 27 twice on the partially scored side)
Bottles of 100 ............................ NDC 0078-0509-05
Do not store above 30°C (86°F). Protect from moisture.
Dispense in tight container (USP).
Meets USP Dissolution Test 2.
XR Tablets 100 mg - round, yellow, coated (imprinted T on one side and 100 mg on the other), release portal on one side
Bottles of 100 ............................ NDC 0078-0510-05
XR Tablets 200 mg - round, pink, coated (imprinted T on one side and 200 mg on the other), release portal on one side
Bottles of 100 ............................. NDC 0078-0511-05
XR Tablets 400 mg - round, brown, coated (imprinted T on one side and 400 mg on the other), release portal on one side
Bottles of 100 ............................. NDC 0078-0512-05
Store at controlled room temperature 15°C-30°C (59°F-86°F). Protect from moisture.
Dispense in tight container (USP).
Suspension 100 mg/5 mL (teaspoon) – yellow-orange, citrus-vanilla flavored
Bottles of 450 mL ........................ NDC 0078-0508-83
Shake well before using.
Do not store above 30°C (86°F). Dispense in tight, light-resistant container (USP).
Distributed by: Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936. January 2014
Last reviewed on RxList: 1/29/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Tegretol Information
Tegretol - User Reviews
Tegretol User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find tips and treatments to control seizures.